Comparison between strontium administration and ibandronate injection effects on bone density of post-ovariectomy Wistar rat

Автор: Bastian D., Martiana I.K.

Журнал: Гений ортопедии @geniy-ortopedii

Рубрика: Оригинальные статьи

Статья в выпуске: 2, 2020 года.

Бесплатный доступ

Introduction Osteoporosis is a disease causing high morbidity with increasing prevalence. It is one of chronic diseases caused by reduced bone mass that subsequently decreases bone strength and increases fracture risks. Pharmacologic treatments for osteoporosis include antiresorptive agent (bisphosphonate) and bone-forming agent (strontium ranelate), so further research is needed to compare these two medications. Objectives We aimed to histopathologically compare bone density in post-menopause white rats after being treated with strontium and ibandronate. Material and methods 45 ovariectomized female rats were divided into three groups. The subjects in the first group were only ovariectomized (control). The strontium group was given daily oral strontium at a dose of 625 mg/kg BW/day for 60 days. The ibandronate group was given one subcutaneous ibandronate injection at a dose of 1 μg/kg BW/day for 60 days. We measured osteoclasts, osteoblasts, trabecula area and cortical thickness. Results The animals in ibandronate and strontium groups showed a significant increase.


Ibandronate, osteoblast, osteoclast, osteoporosis, strontium, trabecula

Короткий адрес:

IDR: 142226222   |   DOI: 10.18019/1028-4427-2020-26-2-212-215

Список литературы Comparison between strontium administration and ibandronate injection effects on bone density of post-ovariectomy Wistar rat

  • D.R. Biphosphonate Treatment on Osteoporosis. Syposium Update on Osteoporosis. 2000. Surabaya, pp 57-77.
  • National Osteoporosis Foundation. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. 1999. Washington DC.
  • Reginster J.Y. Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis. Drugs, 2011, vol. 71, no. 1, pp. 65-78. DOI: 10.2165/11587570-000000000-00000
  • Kwok A.W.L., Leung J.C.S., Chan A.Y.H., Au B.S.K., Lau E.M.C., Yurianto H., Yuktanandana P., Yoshimura N., Muraki S., Oka H., Akune T., Leung P.C. Prevalence of vertebral fracture in Asian men and women: Comparison between Hong Kong, Thailand, Indonesia and Japan. Public Health, 2012, vol. 126, no. 6, pp. 523-531. DOI: 10.1016/j.puhe.2012.03.002
  • Badan Pusat Statistik. Proyeksi Penduduk Indonesia 2010-2035. 2013. Jakarta. BPS-Statistics Indonesia. (In Indonesia)
  • Vestergaard P. New strategies for osteoporosis patients previously managed with strontium ranelate. Therapeutic Advances in Musculoskeletal Disease, 2014, vol. 6, no. 6, pp. 217-225.
  • DOI: 10.1177/1759720X14552070
  • Daroszewska A. Prevention and treatment of osteoporosis in women: an update. Obstetrics Gynaecology and Reproductive Medicine, 2015, vol. 25, no. 7, pp. 181-187.
  • DOI: 10.1016/j.ogrm.2015.04.001
  • Canalis E. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. bone, 1996, vol. 18, no. 6, pp. 517-523.
  • DOI: 10.1016/8756-3282(96)00080-4
  • Zainuddin M. Metodologi Penelitian. 2000. Surabaya. Universitas Airlangga. (In Indonesia)
  • Bauss F., Lalla S., Endele R., Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol., 2002, vol. 29, no. 10, pp. 2200-2208.
  • Bauss F., Schimmer R.C. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag, 2006, vol. 2, no. 1, pp. 3-18.
  • Ammann P., Shen V., Robin B., Mauras Y., Bonjour J.P., Rizzoli R. Strontium Ranelate Improves Bone Resistance by Increasing Bone Mass and Improving Architecture in Intact Female Rats. J. Bone Miner Res., 2004, vol. 19, no. 12, pp. 2012-2020.
  • DOI: 10.1359/jbmr.040906
  • Bain S.D., Jerome C., Shen V., Dupin-Roger I., Ammann P. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int., 2009, vol. 20, no. 8, pp. 1417-1428.
  • DOI: 10.1007/s00198-008-0815-8
  • Knoch F.V., Jaquiery C., Kowalsky M., Schaeren S., Alabre C., Martin I., Rubash H.E., Shanbhag A.S. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials, 2005, vol. 26, no. 34, pp. 6941-6949.
  • DOI: 10.1016/j.biomaterials.2005.04.059
  • Koch F.P., Yekta S.S., Merkel C., Ziebart T., Smeets R. The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro. Head Face Med., 2010, vol. 6, no. 1, pp. 12.
  • DOI: 10.1186/1746-160X-6-12
  • Kharwadkar N., Mayne B., Lawrence J.E., Khanduja V. Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res., 2017, vol. 6, no. 3, pp. 144-153.
  • DOI: 10.1302/2046-3758.63.BJR-2016-0125.R1
Статья научная